3.58
Sana Biotechnology Inc stock is traded at $3.58, with a volume of 3.67M.
It is down -0.56% in the last 24 hours and down -26.49% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
See More
Previous Close:
$3.60
Open:
$3.65
24h Volume:
3.67M
Relative Volume:
0.68
Market Cap:
$851.35M
Revenue:
-
Net Income/Loss:
$-283.26M
P/E Ratio:
-2.4354
EPS:
-1.47
Net Cash Flow:
$-273.61M
1W Performance:
+7.51%
1M Performance:
-26.49%
6M Performance:
+18.94%
1Y Performance:
-37.30%
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Compare SANA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SANA
Sana Biotechnology Inc
|
3.58 | 863.23M | 0 | -283.26M | -273.61M | -1.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-03-25 | Resumed | Morgan Stanley | Overweight |
Mar-18-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
Mar-14-25 | Initiated | Jefferies | Buy |
Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
Nov-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Jun-26-24 | Initiated | Rodman & Renshaw | Buy |
Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
Sep-05-23 | Initiated | Citigroup | Buy |
Aug-14-23 | Initiated | TD Cowen | Market Perform |
May-02-23 | Initiated | H.C. Wainwright | Neutral |
Mar-01-21 | Initiated | BofA Securities | Buy |
Mar-01-21 | Initiated | Goldman | Neutral |
Mar-01-21 | Initiated | JP Morgan | Neutral |
Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
Sana Biotechnology Reports Q2 2025 Financial Results - TipRanks
Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
$86.3 Million Capital Raise: Sana Biotechnology Strengthens Position with Successful Share Offering Completion - Stock Titan
Sentiment Tools Show Shift in Trader Mood on Sana Biotechnology Inc.Market Trend Review & Stepwise Entry/Exit Trade Alerts - classian.co.kr
Sana Biotechnology Inc. Sees Spike in Bullish Option FlowJuly 2025 Trends & Verified Momentum Stock Watchlist - newsimpact.co.kr
Screener Results Flag Sana Biotechnology Inc. as Oversold2025 Buyback Activity & Comprehensive Market Scan Reports - classian.co.kr
Quant Funds Rotate Into Sana Biotechnology Inc. Stock2025 Earnings Impact & Daily Volume Surge Signals - newsyoung.net
What institutional flow reveals about Sana Biotechnology Inc.2025 Breakouts & Breakdowns & Intraday High Probability Alerts - Newser
Can you recover from losses in Sana Biotechnology Inc.July 2025 Fed Impact & Community Shared Stock Ideas - Newser
Does Sana Biotechnology Inc. qualify in momentum factor screening2025 Key Lessons & Free Real-Time Market Sentiment Alerts - Newser
Will Sana Biotechnology Inc. bounce back from current support2025 Trading Recap & AI Driven Price Predictions - Newser
Can machine learning forecast Sana Biotechnology Inc. recoveryMarket Activity Summary & Capital Efficiency Focused Strategies - Newser
Using flow based indicators on Sana Biotechnology Inc.Trade Exit Summary & Daily Technical Stock Forecast Reports - Newser
Tools to assess Sana Biotechnology Inc.’s risk profileDip Buying & Free Fast Entry Momentum Trade Alerts - Newser
How sentiment analysis helps forecast Sana Biotechnology Inc.2025 Price Momentum & AI Based Trade Execution Alerts - Newser
Is it time to cut losses on Sana Biotechnology Inc.M&A Rumor & Stock Portfolio Risk Control - Newser
Will breakout in Sana Biotechnology Inc. lead to full recoveryJuly 2025 Drop Watch & Free Weekly Watchlist of Top Performers - Newser
Sana Biotechnology Inc. stock trend forecastVolume Spike & Weekly Watchlist of Top Performers - Newser
What momentum shifts mean for Sana Biotechnology Inc.July 2025 Trends & Community Consensus Trade Alerts - Newser
Smart tools for monitoring Sana Biotechnology Inc.’s price actionEarnings Trend Report & Verified Short-Term Trading Plans - Newser
How to read the order book for Sana Biotechnology Inc.Market Sentiment Report & Fast Entry High Yield Stock Tips - Newser
Sana Biotechnology's Promising Advances in Diabetes Treatment Support Buy Rating - AInvest
Sana Biotechnology shares rise 6.34% intraday after positive clinical results and FDA meeting. - AInvest
Sana Biotech Bails on Factory in Old AT&T Call Center - Yahoo Finance
Sana Biotechnology’s Strategic Advances and Positive FDA Feedback Bolster Buy Rating - TipRanks
Sana: Q2 Earnings Snapshot - Connecticut Post
Is Sana Biotechnology Inc. stock a value trapGolden Crossover Alert - kangso.co.kr
Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Sana Biotechnology SANA 2025Q2 Earnings Preview Upside Expected with New Product Pipeline Developments - AInvest
Institutional Investors May Adopt Severe Steps After Sana Biotechnology, Inc.'s (NASDAQ:SANA) Latest 29% Drop Adds to a Year Losses - 富途牛牛
Will Sana Biotechnology Inc. benefit from macro trendsFree High Yield Stock Screening Results - Newser
Sana suspends build-out of Bothell manufacturing facility - The Business Journals
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of “Buy” by Brokerages - Defense World
Is Sana Biotechnology Inc. stock poised for growthWeekly Signal Report with Trend Summary - Newser
Sana Biotechnology: A High-Risk, High-Reward Play on a Potential Diabetes Cure - AInvest
Reversal indicators forming on Sana Biotechnology Inc. stockSwing Trade Entry and Exit Point Analysis - Newser
Sana Biotechnology drops 13% on $75M stock issuance, prices at $3.35 - MSN
Sana Biotechnology options signal 10.8% potential stock price movement after earnings - AInvest
Sana Biotechnology (SANA) Rated ‘Market Perform’ on Diabetes Program Prospects - MSN
Sana Biotechnology Announces Public Offering Pricing - The Globe and Mail
Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued (NASDAQ:SANA) - Seeking Alpha
Sana Biotechnology shares rise 3.03% premarket after pricing $75 million share offering. - AInvest
Sana Biotechnology Announces Pricing of Public Offering - GlobeNewswire
Seattle biotech firm Sana Biotechnology raising $75 million through public offering - The Business Journals
Sana Biotechnology Announces $69.9mln Public Offering of 20.9mln Shares - AInvest
ALRM shifts unused 2015 shares to 2025 equity plan; no new dilution | SANA SEC FilingForm 8-K - Stock Titan
Sana Biotechnology (SANA.O) Plummets 28% – What’s Behind the Sudden Drop? - AInvest
Sana Biotechnology Plummets 30.5% Intraday: A Technical and Order-Flow Deep Dive - AInvest
Sana Biotechnology Plummets 30%: A Bearish Storm Unfolds as Capital Raise Sparks Investor Exodus - AInvest
Sana Biotechnology stock tumbles after pricing public offering By Investing.com - Investing.com Canada
Sana Biotechnology stock tumbles after pricing public offering - Investing.com
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sana Biotechnology Inc Stock (SANA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Cassidy Bernard J | EVP & General Counsel |
Mar 07 '25 |
Option Exercise |
0.00 |
11,041 |
0 |
115,823 |
Harr Steve | President & CEO |
Mar 07 '25 |
Option Exercise |
0.00 |
50,000 |
0 |
7,889,750 |
Wyrick Susan D. | See Remarks |
Mar 02 '25 |
Option Exercise |
0.00 |
1,525 |
0 |
155,471 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):